Home Newsfeeds RBC Capital Reiterates Outperform on Verisk Analytics, Maintains $210 Price Target

RBC Capital Reiterates Outperform on Verisk Analytics, Maintains $210 Price Target

RBC Capital analyst Ashish Sabadra reiterates Verisk Analytics (NASDAQ:VRSK) with a Outperform and maintains $210 price target.

byBenzinga Newsdesk

March 15, 2023

1 minute read

RBC Capital analyst Ashish Sabadra reiterates Verisk Analytics (NASDAQ:VRSK) with a Outperform and maintains $210 price target.

Analyst Ratings

What 4 Analyst Ratings Have To Say About AutoZone

By Benzinga Insights

September 8, 4:00 PM

Within the last quarter, AutoZone (NYSE:AZO) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish…

AZO

This Crypto Is Up Over 18% Weekly, Leaving Bitcoin, Ethereum And Dogecoin In The Dust

By Mehab Qureshi

November 21, 2:41 AM

LEO (CRYPTO:LEO), the native token of crypto exchange Bitfinex, is rallying as the overall crypto market struggles to gain footing. The utility token was up 18% in the past seven days, trading at $4.44, recorded on Monday, 12 a.m. EST.

$APE

Mizuho Maintains Buy on Exelon, Lowers Price Target to $39

By Benzinga Newsdesk

November 4, 12:58 PM

Mizuho analyst Paul Fremont maintains Exelon (NASDAQ:EXC) with a Buy and lowers the price target from $47 to $39.

EXC

Benchmark Maintains Buy on ATI Physical Therapy, Lowers Price Target to $2

By Benzinga Newsdesk

August 10, 10:17 AM

Benchmark analyst Bill Sutherland maintains ATI Physical Therapy (NYSE:ATIP) with a Buy and lowers the price target from $4 to $2.

ATIP

RBC Capital Reiterates Outperform on Verisk Analytics, Maintains $210 Price Target

Related Posts

What 4 Analyst Ratings Have To Say About AutoZone

This Crypto Is Up Over 18% Weekly, Leaving Bitcoin, Ethereum And Dogecoin In The Dust

Mizuho Maintains Buy on Exelon, Lowers Price Target to $39

Benchmark Maintains Buy on ATI Physical Therapy, Lowers Price Target to $2